Equinor ASA: Eks. utbytte
Fra og med 12. mai 2021 vil aksjene i Equinor (OSE: EQNR, NYSE: EQNR) noteres eks. utbytte 0,12 USD.
Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12
Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.
Om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeldinger fra GlobeNewswire by notified
Registrer deg med din e-postadresse under for å få de nyeste sakene fra GlobeNewswire by notified på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra GlobeNewswire by notified
Havila Kystruten AS: Havila Pollux Cancels Upcoming Round Trip8.5.2024 23:15:38 CEST | Press release
Havila Pollux has been docked in Bergen since May 2nd for planned warranty work, after an electro motor supplying power to the propulsion system had to be replaced. In recent days, testing of the new electro motor has been conducted, during which a malfunction was discovered in a bearing in the underwater housing of one of the propellers (azimuth POD). Sailing the ship in service with this malfunction is not deemed safe, and the newly discovered issue must be rectified. Consequently, Havila Pollux will sail to GMC in Stavanger to be placed in dry-dock for the replacement of the propeller's underwater housing. This replacement is also considered warranty work. As a result, the upcoming round trip departing from Bergen on May 13th will be cancelled. Considering the necessary preparations by the Norwegian equipment supplier and the replacement of the underwater housing, it is expected that Havila Pollux will resume its regular service from Bergen no later than May 24th. All affected passe
Havila Kystruten AS: Havila Pollux kansellerer kommende rundtur8.5.2024 23:15:38 CEST | Pressemelding
Havila Pollux har siden 2. mai ligget til kai i Bergen for planlagte garantiarbeider, etter at en elektromotor som forsyner propellsystemet med kraft måtte byttes ut. De siste dagene har det vært utført testing av den nye elektromotoren, og i forbindelse med det er det oppdaget en feil på et lager i undervannshuset til den ene propellen (azimut POD). Å seile skipet i rute med denne feilen er ikke sikkerhetsmessig forsvarlig, og den nyoppdagede feilen må utbedres. Havila Pollux vil derfor seile til GMC i Stavanger for å settes i tørrdokk for bytte av undervannshuset til propellen. Denne utskiftingen anses også som garantiarbeid. Den kommende rundturen med avgang fra Bergen 13. mai vil derfor kanselleres. Hensyntatt nødvendige forberedelser fra den norske utstyrsleverandøren samt utskiftning av undervannshuset, er det er forventet at Havila Pollux er tilbake i rute igjen fra Bergen senest 24. mai. Alle berørte passasjerer blir kontaktet av Havila Kystruten. Kontakter: Administrerende dir
Update on EIB Support for Europe's Security and Defence Industry8.5.2024 23:12:56 CEST | Press release
For immediate release 8 May 2024 EIB submits SEC Form 18-K/A Amendment No. 1 The European Investment Bank (EIB) has submitted its SEC Form 18-K/A Amendment No. 1. To view the document, please go to: sec.gov/Archives/edgar/data/33745/000095015724000719/form18k-a.htm The 18-K/A has also been posted on the EIB website: Amendment to the Annual Report 2023 (Form 18-K/A Amendment No 1) (eib.org) ENDS
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update8.5.2024 22:15:38 CEST | Press release
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update. “At the upcoming 2024 ASCO meeting, we are looking forward to presenting multiple datasets including the first clinical data on safety and efficacy of petosemtamab in combination with pembrolizumab in previously untreated head and neck cancer. With p
CrossAmerica Partners LP Reports First Quarter 2024 Results8.5.2024 22:15:00 CEST | Press release
Allentown, PA, May 08, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2024 Results Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023Reported First Quarter 2024 Gross Profit for the Wholesale Segment of $27.0 million compared to $31.2 million of Gross Profit for the First Quarter 2023 and First Quarter 2024 Gross Profit for the Retail Segment of $54.4 million compared to $50.8 million of Gross Profit for the First Quarter 2023Leverage, as defined in the CAPL Credit Facility, was 4.49 times as of March 31, 2024, compared to 4.21 times as of December 31, 2023The Distribution Coverage Ratio for the trailing twelve months ended March 31, 2024 was 1.37 times compared to 1